High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis.

ABSTRACT:

Background

Though pharmacokinetic studies suggest accelerated biologic drug clearance with increasing body weight, evidence of obesity's impact on clinical outcomes in biologic-treated patients with ulcerative colitis (UC) is inconsistent.

Aim

To evaluate the impact of obesity on real world response to biological therapy in patients with UC.

Methods

In a single-centre retrospective cohort study between 2011-2016 of biologic-treated patients with UC, we evaluated treatment response by baseline body mass index (BMI). Primary outcome was treatment failure (composite outcome of IBD-related surgery/hospitalisation or treatment modification including dose escalation, treatment discontinuation or addition of corticosteroids); secondary outcomes were risk of IBD-related surge

SUBMITTER: Kurnool S 

PROVIDER: S-EPMC5992082 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature